Want to see DE:M12 full AI Analyst Report?
Top Page
M1 Kliniken AG
(XETRA:M12)
Select Model
Select Model
Rating:79Outperform
Price Target:
€23.00
▲(25.27% Upside)
Action:Reiterated
Date:10/10/26
Overall score is driven primarily by solid financial performance (growing revenues, much higher earnings vs 2022, strong recent cash generation, and low leverage). Valuation adds support through a moderate P/E and a high dividend yield, while technicals are positive but not strong, reflecting a longer-term uptrend with near-term consolidation and neutral momentum.
Positive Factors
Conservative balance sheet
Very low leverage reduces financing pressure and preserves flexibility for clinic expansion, investment, or shareholder returns. Growing equity provides an additional buffer against operating volatility, while modest debt limits the drag from interest costs over the next several quarters.
Negative Factors
Revenue growth is slowing
The continued deceleration in annual revenue growth indicates that expansion and demand momentum are moderating. If this pattern persists, slower top-line progression could limit operating leverage, reduce the pace of earnings growth, and make future performance more dependent on margin improvement.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Very low leverage reduces financing pressure and preserves flexibility for clinic expansion, investment, or shareholder returns. Growing equity provides an additional buffer against operating volatility, while modest debt limits the drag from interest costs over the next several quarters.
Read all positive factors
M1 Kliniken AG (M12) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€349.68M
Dividend Yield6.04%
Average Volume (3M)4.93K
Price to Earnings (P/E)18.2
Beta (1Y)0.32
Revenue Growth-27.50%
EPS Growth13.64%
CountryDE
Employees280
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)1.09
Shares Outstanding18,555,115
10 Day Avg. Volume3,493
30 Day Avg. Volume4,934
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)2.94
Price to Sales (P/S)0.97
P/FCF Ratio9.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.03
Revenue Forecast (FY)€137.00M
M1 Kliniken AG Business Overview & Revenue Model
Company Description
M1 Kliniken AG, a Berlin, Germany-based entity established in 2007 and operating as a subsidiary of MPH Health Care AG, manages medical facilities dedicated to aesthetic and plastic surgery across Germany, Austria, the Netherlands, Switzerland, th...
How the Company Makes Money
M1 Kliniken AG generates revenue mainly from two business areas. (1) Aesthetics/clinic operations: The company earns money by providing aesthetic medical treatments directly to patients in its clinic network. Revenue is recognized from patient-pai...
M1 Kliniken AG Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
86
Very Positive
Cash Flow
82
Very Positive
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 257.36M | 364.30M | 339.18M | 316.32M | 285.29M | 314.61M |
| Gross Profit | 47.67M | 47.43M | 63.60M | 32.47M | 21.72M | 26.06M |
| EBITDA | 36.64M | 40.49M | 33.38M | 21.79M | 16.07M | 19.78M |
| Net Income | 20.23M | 22.13M | 16.02M | 10.27M | 4.32M | 8.91M |
Balance Sheet | ||||||
| Total Assets | 177.40M | 189.29M | 187.87M | 212.95M | 197.02M | 198.11M |
| Cash, Cash Equivalents and Short-Term Investments | 60.50M | 42.00M | 23.69M | 22.76M | 47.50M | 49.12M |
| Total Debt | 5.90M | 10.26M | 10.42M | 17.04M | 19.67M | 30.93M |
| Total Liabilities | 25.14M | 39.28M | 53.65M | 69.73M | 53.97M | 58.21M |
| Stockholders Equity | 124.18M | 119.93M | 106.10M | 113.25M | 95.52M | 95.03M |
Cash Flow | ||||||
| Free Cash Flow | 23.08M | 37.84M | 29.55M | 6.80M | 19.25M | 14.32M |
| Operating Cash Flow | 23.29M | 37.95M | 30.55M | 7.81M | 21.02M | 15.66M |
| Investing Cash Flow | 22.41M | -645.81K | -5.67M | -9.36M | -1.77M | 213.19K |
| Financing Cash Flow | -13.07M | -13.41M | -30.44M | -14.81M | -21.97M | 4.03M |
M1 Kliniken AG Technical Analysis
Neutral
18.36
Price Trends
19.56
Positive
18.57
Positive
17.05
Positive
Market Momentum
0.13
Positive
48.19
Neutral
21.02
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:M12, the sentiment is Neutral. The current price of 18.36 is below the 20-day moving average (MA) of 20.29, below the 50-day MA of 19.56, and above the 200-day MA of 17.05, indicating a neutral trend. The MACD of 0.13 indicates Positive momentum. The RSI at 48.19 is Neutral, neither overbought nor oversold. The STOCH value of 21.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for DE:M12.
M1 Kliniken AG Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | €349.68M | 18.24 | 16.58% | 6.04% | -27.50% | 13.64% | |
67 Neutral | €162.00M | 29.22 | 22.18% | 1.85% | 35.46% | 17.88% | |
66 Neutral | €23.62B | 15.40 | 7.89% | 2.48% | 5.30% | 35.29% | |
64 Neutral | €244.63M | 8.47 | 11.54% | 0.78% | 2.94% | -14.28% | |
59 Neutral | €963.91M | 22.50 | 3.18% | 1.39% | 4.91% | 11.71% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | €18.66M | -1.37 | 16.80% | ― | 2.73% | -1.80% |
* Healthcare Sector Average
DE:M12
M1 Kliniken AG
19.88
5.16
35.10%
DE:FRE
Fresenius SE & Co. KGaA
42.36
-4.40
-9.42%
DE:MED
MEDICLIN
5.15
1.91
58.71%
DE:RHK
RHON-KLINIKUM AG
14.40
2.79
24.02%
DE:MAK
MATERNUS-Kliniken AG
0.89
-0.20
-18.35%
DE:LIK
Limes Schlosskliniken AG
540.00
179.01
49.59%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.